Special ReportsAll NewsFDA BriefsOncology IconsThe Targeted PulseVoices from the Field
Conference CoverageConference ListingData Dialogue with the Oncology Brothers
All VideosCase-Based Peer PerspectivesEvolving Paradigms in OncologyExpert Perspective Virtual Tumor BoardInterviewsInvestigator PerspectivesMedical World NewsPivotal Practice Views with the Oncology BrothersPodcastsSpeaking Out
All PublicationsEvolving ParadigmsPeers & Perspectives in OncologyTargeted Therapies in Oncology
CASE-BASED ROUNDTABLEPARTNERS
CME/CEClinical TrialsEventsPrecision Medicine PerspectivesPress ReleasesSponsored ContentTreatment Resources
SUBSCRIBE
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
Spotlight -
  • Biomarker-Driven Lung Cancer
  • GIST
  • HER2 Breast Cancer
  • Chronic Lymphocytic Leukemia
  • Small Cell Lung Cancer
  • Renal Cell Carcinoma
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
    • CASE-BASED ROUNDTABLE
    • PARTNERS
    • SUBSCRIBE
Advertisement
Emergent Advances and Subgroup Data in ER+, HER2- Metastatic Breast Cancer from SABCS 2023 : Episode 4

Navigating Endocrine Resistance in the Treatment of ER+/HER2- Metastatic Breast Cancer

December 8, 2023
By Hope S. Rugo, MD
Opinion
Video

Current treatment landscape in ER+/HER2- metastatic breast cancer and unmet needs in overcoming treatment resistance.

Video Player is loading.
Current Time 0:00
/
Duration 0:00
Loaded: 0%
0:00
Stream Type LIVE
Remaining Time -0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions settings, opens captions settings dialog
    • captions off, selected
    • en (Main), selected

    This is a modal window.

    Beginning of dialog window. Escape will cancel and close the window.

    Text
    Background
    Window
    Font Size
    Text Edge Style
    Font Family

    End of dialog window.

    This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

    EP: 1.Treatment Landscape in ER+/HER2- Metastatic Breast Cancer and Unmet Needs

    EP: 2.EMERALD Subgroup Analysis in Patients With Visceral and Bone Metastases: Clinical Implication

    EP: 3.Evaluating the Impact of Elacestrant Use in Clinical Practice for Patients With ER+/HER2-Metastasized Breast Cancer

    Now Viewing

    EP: 4.Navigating Endocrine Resistance in the Treatment of ER+/HER2- Metastatic Breast Cancer

    EP: 5.EMERALD Subgroup Analysis in Patients with Coexisting PIK3CA and TP53 Mutations

    EP: 6.Expert Insights in Overcoming Endocrine Resistance for Patients With ER+/HER2- Metastatic Breast Cancer

    EP: 7.The Evolving Treatment Landscape in ER+/HER2- Low Metastatic Breast Cancer

    EP: 8.EMERALD Subgroup Analysis in HER2-Low Metastatic Breast Cancer: Safety and Efficacy of Elacestrant

    EP: 9.Elacestrant in Clinical Practice for Patients with ER+/HER2-Low Metastatic Breast Cancer

    Recent Videos
    Genomic Differences Impact Real World Use of Elacestrant in Breast Cancer
    Genomic Differences Impact Real World Use of Elacestrant in Breast Cancer
    Breast Cancer Study Shows Minimal Score Variation After Radiation Boost
    Breast Cancer Study Shows Minimal Score Variation After Radiation Boost
    Targeting ESR1 Mutations in Breast Cancer With Novel Therapies
    Targeting ESR1 Mutations in Breast Cancer With Novel Therapies
    Shortened Radiation Trial Advances Breast Cancer Treatment
    Shortened Radiation Trial Advances Breast Cancer Treatment
    Understanding the Significance of ESR1 Mutations in Breast Cancer
    Understanding the Significance of ESR1 Mutations in Breast Cancer
    42nd Annual Miami Breast Cancer Conference: The Show and After Show
    42nd Annual Miami Breast Cancer Conference: The Show and After Show
    Considering Elacestrant in ESR1+ Breast Cancer After CDK4/6 Inhibition
    Considering Elacestrant in ESR1+ Breast Cancer After CDK4/6 Inhibition
    Best Practices and Strategies for Luspatercept in the Treatment of LR-MDS
    Best Practices and Strategies for Luspatercept in the Treatment of LR-MDS
    Future Outlook in Front-line Treatment for uHCC.
    Future Outlook in Front-line Treatment for uHCC.
    Sequencing and AEs Guide Next Steps for Dato-DXd in Breast Cancer
    Sequencing and AEs Guide Next Steps for Dato-DXd in Breast Cancer
    Related Content
    Treating Metastatic Breast Cancer After Endocrine Therapy and T-DXd

    Treating Metastatic Breast Cancer After Endocrine Therapy and T-DXd

    Targeted Oncology Staff
    March 31st 2025
    Article

    During a live event, Payal D. Shah, MD, discusses the case of a woman with metastatic breast cancer and the data for third-line sacituzumab govitecan.

    Read More

    Behind the FDA Approval of Dato-DXd in HR+/HER2– Breast Cancer With Bardia

    Behind the FDA Approval of Dato-DXd in HR+/HER2– Breast Cancer With Bardia

    Jordyn Sava;Aditya Bardia, MD, MPH
    February 6th 2025
    Podcast

    In this episode of Targeted Talks, Aditya Bardia, MD, MPH, FASCO, discusses the recent FDA approval of datopotamab deruxtecan in breast cancer.

    Listen

    Sacituzumab Govitecan Shows Consistent Efficacy in Real-World mTNBC

    Sacituzumab Govitecan Shows Consistent Efficacy in Real-World mTNBC

    Ashling Wahner
    March 14th 2025
    Article

    In metastatic triple-negative breast cancer, sacituzumab govitecan was effective and tolerable in the real-world setting.

    Read More

    Juneja Explores AI’s Impact in Early Cancer Detection and Treatment

    Juneja Explores AI’s Impact in Early Cancer Detection and Treatment

    Jordyn Sava;Sanjay K. Juneja, MD
    January 15th 2025
    Podcast

    In this episode of Targeted Talks, Sanjay K. Juneja, MD, discusses the exciting advancements of artificial intelligence in 2024.

    Listen

    Immunotherapies Spark Excitement in Triple-Negative Breast Cancer Treatment

    Immunotherapies Spark Excitement in Triple-Negative Breast Cancer Treatment

    Tony Berberabe, MPH
    March 8th 2025
    Article

    Immunotherapy advances in triple-negative breast cancer drive personalized treatments with immune checkpoint inhibitors, aiding subtype identification and new combination therapy developments.

    Read More

    HR+/MP-H2 Breast Cancers Resemble Triple-Negative, Guiding New Therapies

    HR+/MP-H2 Breast Cancers Resemble Triple-Negative, Guiding New Therapies

    Jordyn Sava
    March 3rd 2025
    Article

    Alejandro Rios Hoyo discussed findings on a subset of hormone receptor–positive, HER2-negative breast cancers classified as MP-H2.

    Read More

    Related Content
    Investigator Perspectives
    |
    BREAST CANCER
    |
    Emergent Advances and Subgroup Data in ER+, HER2- Metastatic Breast Cancer from SABCS 2023
    Treating Metastatic Breast Cancer After Endocrine Therapy and T-DXd

    Treating Metastatic Breast Cancer After Endocrine Therapy and T-DXd

    Targeted Oncology Staff
    March 31st 2025
    Article

    During a live event, Payal D. Shah, MD, discusses the case of a woman with metastatic breast cancer and the data for third-line sacituzumab govitecan.

    Read More

    Behind the FDA Approval of Dato-DXd in HR+/HER2– Breast Cancer With Bardia

    Behind the FDA Approval of Dato-DXd in HR+/HER2– Breast Cancer With Bardia

    Jordyn Sava;Aditya Bardia, MD, MPH
    February 6th 2025
    Podcast

    In this episode of Targeted Talks, Aditya Bardia, MD, MPH, FASCO, discusses the recent FDA approval of datopotamab deruxtecan in breast cancer.

    Listen

    Sacituzumab Govitecan Shows Consistent Efficacy in Real-World mTNBC

    Sacituzumab Govitecan Shows Consistent Efficacy in Real-World mTNBC

    Ashling Wahner
    March 14th 2025
    Article

    In metastatic triple-negative breast cancer, sacituzumab govitecan was effective and tolerable in the real-world setting.

    Read More

    Juneja Explores AI’s Impact in Early Cancer Detection and Treatment

    Juneja Explores AI’s Impact in Early Cancer Detection and Treatment

    Jordyn Sava;Sanjay K. Juneja, MD
    January 15th 2025
    Podcast

    In this episode of Targeted Talks, Sanjay K. Juneja, MD, discusses the exciting advancements of artificial intelligence in 2024.

    Listen

    Immunotherapies Spark Excitement in Triple-Negative Breast Cancer Treatment

    Immunotherapies Spark Excitement in Triple-Negative Breast Cancer Treatment

    Tony Berberabe, MPH
    March 8th 2025
    Article

    Immunotherapy advances in triple-negative breast cancer drive personalized treatments with immune checkpoint inhibitors, aiding subtype identification and new combination therapy developments.

    Read More

    HR+/MP-H2 Breast Cancers Resemble Triple-Negative, Guiding New Therapies

    HR+/MP-H2 Breast Cancers Resemble Triple-Negative, Guiding New Therapies

    Jordyn Sava
    March 3rd 2025
    Article

    Alejandro Rios Hoyo discussed findings on a subset of hormone receptor–positive, HER2-negative breast cancers classified as MP-H2.

    Read More

    Advertisement
    Advertisement
    Advertisement
    x
    About Us
    Advertise
    Contact Us
    CureToday.com
    CancerNetwork.com
    OncLive.com
    OncNursingNews.com
    Do Not Sell My Information
    Privacy
    Terms & Conditions
    Editorial Board
    Contact Info

    2 Commerce Drive
    Cranbury, NJ 08512

    609-716-7777

    © 2025 MJH Life Sciences

    All rights reserved.